Xcout Intel
Excalipoint competitors & alternatives
The 12 closest competitors and alternatives to Excalipoint among biotech companies — ranked by similarity to what Excalipoint actually does, not by market-cap band.
Subscribe to see Excalipoint’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Excalipoint
Excalipoint Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China. The firm is dedicated to developing next-generation T-cell engager (TCE) therapies and unlocking the therapeutic potential of T-cell based treatments.
Excalipoint at a glance
Excalipoint is a biotech company headquartered in China. Its most recent funding round, Seed, raised $68.7M in March 2026. Xcout tracks 1 named person at Excalipoint, including Lei Fang (co-founder, chairman, and CEO).
Excalipoint leadership
- Lei Fangco-founder, chairman, and CEO
Excalipoint funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $68.7M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Excalipoint competitors
Ranked by semantic similarity — how close each company is to Excalipoint by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Biotechnology
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms and first-in-class T-cell therapies to access cancer-specific targets.
Biotechnology
Allink Biotherapeutics is a clinical-stage biotechnology company founded in 2023 and based in Shanghai, China, focused on developing advanced antibody-drug conjugates (ADCs) and therapeutics.
Biotechnology
Carcell Biopharma Inc. is an EVX company that develops next-generation cell and gene therapies utilizing a "platform of platforms" model. Based in both Singapore and Shanghai, the company focuses on advancing innovative treatments in the biotechnology sector.
Biotechnology
Lyvgen Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immune-oncology therapies. Founded in 2016, the company maintains its headquarters in Shanghai, China, alongside research facilities in Suzhou.
Biotechnology
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
Biotechnology
92Bio is a clinical-stage biotechnology company headquartered in Hayward, California, that develops next-generation T-cell engaging antibodies for therapeutic treatments.
Similar biotech company
Tessa Therapeutics is a clinical-stage biotechnology company with its global headquarters in Singapore. The company focuses on developing next-generation cell therapies for cancer and opened a commercial-scale cell therapy manufacturing facility in Singapore in 2020.
Biotechnology
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
Similar biotech company
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
Similar biotech company
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
Biotechnology
Flashpoint Therapeutics is a clinical-stage biotechnology research company headquartered in Evanston, Illinois, developing a new class of precision-engineered structural nanomedicines through its proprietary platform.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Excalipoint and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Excalipointand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →